Satraplatin: A new treatment option for patients with hormone refractory prostate cancer.

被引：0
|
作者：
Nathan, FE
Sternberg, C
Sartor, O
Petrylak, D
Witjes, F
Wosikowski, K
Petrone, ME
Rozencweig, M
机构：
[1] GPC Biotech Inc, Princeton, NJ USA
[2] San Camillo Hosp, Rome, Italy
[3] Forlanini Hosp, Rome, Italy
[4] LSU, Sch Med, New Orleans, LA USA
[5] Columbia Presbyterian Med Ctr, New York, NY 10032 USA
[6] Acad Ziekenhuis, Nijmegen, Netherlands
[7] GPC Biotech AG, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：453S / 453S
页数：1
相关论文
共 50 条
  • [41] Satraplatin in Second-line of Castration-resistant Prostate cancer.
    Heidenreich, A.
    ONKOLOGE, 2010, 16 (03): : 314 - 315
  • [42] Paclitaxel in the treatment of hormone-refractory prostate cancer
    Smith, DC
    Pienta, KJ
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 109 - 111
  • [43] Treatment options for hormone-refractory prostate cancer
    Heidenreich, A
    Ohlmann, CH
    UROLOGE, 2005, 44 (11): : 1303 - +
  • [44] Treatment with prednisolone of hormone-refractory prostate cancer
    Fuse, H
    Nozaki, T
    Fujiuchi, Y
    Mizuno, I
    Nagakawa, O
    Okumura, A
    ARCHIVES OF ANDROLOGY, 2006, 52 (01): : 35 - 38
  • [45] Megestrol acetate in the treatment of hormone refractory prostate cancer
    Osborn, JL
    Smith, DC
    Trump, DL
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (03): : 308 - 310
  • [46] Chemotherapy for the treatment of hormone-refractory prostate cancer
    Petrylak, DP
    EUROPEAN UROLOGY SUPPLEMENTS, 2002, 1 (02) : 15 - 23
  • [47] Pyrazoloacridine for the treatment of hormone-refractory prostate cancer
    Small, EJ
    Fippin, LJ
    Whisenant, SP
    CANCER INVESTIGATION, 1998, 16 (07) : 456 - 461
  • [48] NEW AGENTS IN THE THERAPY OF HORMONE-REFRACTORY PATIENTS WITH PROSTATE-CANCER
    KANTOFF, PW
    SEMINARS IN ONCOLOGY, 1995, 22 (01) : 32 - 34
  • [49] Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer. A possibility for secondary hormonal ablation?
    Schilling, D.
    Kuefer, R.
    Kruck, S.
    Stenzl, A.
    Kuczyk, M. A.
    Merseburger, A. S.
    UROLOGE, 2008, 47 (10): : 1334 - 1338
  • [50] Chemotherapy for patients with hormone-refractory prostate cancer
    Joly, F
    Tannock, IF
    ANNALS OF ONCOLOGY, 2004, 15 (11) : 1582 - 1584
12345